Brief: SynAct Pharma Q1 Sales SEK 0
27/05/2026 06:31
BRIEF-SynAct Pharma Q1 Sales SEK 0 May 27 (Reuters) - SynAct Pharma Q1 operating expenses SEK 30.558 million.
- Q1 net income SEK -25.487 million
- Q1 adjusted EPS SEK -0.48
- Q1 cash flow from operating activities SEK -32.952 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development